Skip to main content

Advertisement

SpringerLink
Log in

Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Alendronate is effective in preventing second hip fracture in osteoporotic patients. However, no consensus exists on the duration that is effective in preventing a second hip fracture. Our study demonstrated that risk can be reduced when the prescription is ≥ 6 months for the year following the index hip fracture.

Introduction

Alendronate is effective in preventing second hip fracture in osteoporotic patients. However, no consensus exists on the accurate medication possession ratio (MPR) that is effective in preventing a second hip fracture. Our objective was to compare the risk of second hip fracture in patients treated with different MPR of alendronate.

Methods

In this population-based cohort study, data from National Health Insurance Research Database of Taiwan were analyzed. Patients 50 years and older who had an index hip fracture and were not receiving any osteoporotic medications before their fracture during 2000–2010 were included. The cohort consisted of 88,320 patients who were new alendronate users (n = 9278) and non-users (n = 79,042). Those without alendronate were matched 4:1 as the control group. Patients were subdivided into those with no medication, MPR < 25%, MPR 25–50%, MPR 50–75%, and MPR 75–100%. Cox proportional hazard models were used to calculate the adjusted hazard ratios for different MPRs of alendronate.

Results

After matching, 38,675 patients were included in this study; 20,363 (52.7%) were women, and 30,940 (80%) patients were without medication of alendronate. During follow-up on December 31, 2012, 2392 patients had a second hip fracture, for an incidence of 1449/100,000 person-years. Patients with alendronate MPR 50–75% had a lower risk of a second hip fracture compared to non-users (hazard ratio 0.66). When the MPR increased to 75–100%, the hazard ratio decreased to 0.61.

Conclusions

In this population-based cohort study, risk of a second hip fracture can be reduced when the alendronate MPR is ≥ 50% for the year following the index hip fracture. As the MPR increases, the risk of a second hip fracture decreases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Colon-Emeric CS, Sloane R, Hawkes WG, Magaziner J, Zimmerman SI, Pieper CF et al (2000) The risk of subsequent fractures in community-dwelling men and male veterans with hip fracture. Am J Med 109:324–326

    Article  CAS  Google Scholar 

  2. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739

    Article  CAS  Google Scholar 

  3. Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569–1575

    Article  Google Scholar 

  4. Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585–594

    Article  CAS  Google Scholar 

  5. Nguyen ND, Eisman JA, Nguyen TV (2006) Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res 21:340–349

    Article  CAS  Google Scholar 

  6. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022

    Article  Google Scholar 

  7. Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O (2017) Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. Medicare population. J Manag Care Spec Pharm 23:1178–1190

    PubMed  Google Scholar 

  8. Lee YK, Ha YC, Choi HJ, Jang S, Park C, Lim YT, Shin CS (2013) Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int 24:2887–2892

    Article  CAS  Google Scholar 

  9. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809

    Article  CAS  Google Scholar 

  10. Morin S, Rahme E, Behlouli H, Tenenhouse A, Goltzman D, Pilote L (2007) Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures. Osteoporos Int 18:1625–1632

    Article  CAS  Google Scholar 

  11. Peng J, Liu Y, Chen L, Peng K, Xu Z, Zhang D, Xiang Z (2016) Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: a meta-analysis. Pak J Med Sci 32:499–504

    PubMed  PubMed Central  Google Scholar 

  12. Vestergaard P, Rejnmark L, Mosekilde L (2011) Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif Tissue Int 88:209–214

    Article  CAS  Google Scholar 

  13. Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460

    Article  CAS  Google Scholar 

  14. Lee YK, Ha YC, Yoon BH, Koo KH (2013) Incidence of second hip fracture and compliant use of bisphosphonate. Osteoporos Int 24:2099–2104

    Article  CAS  Google Scholar 

  15. Olsen KR, Hansen C, Abrahamsen B (2013) Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. Osteoporos Int 24:2639–2647

    Article  CAS  Google Scholar 

  16. Wang YH, Kung PT, Tsai WC, Tai CJ, Liu SA, Tsai MH (2012) Effects of multidisciplinary care on the survival of patients with oral cavity cancer in Taiwan. Oral Oncol 48:803–810

    Article  Google Scholar 

  17. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287

    Article  CAS  Google Scholar 

  18. Hawley S, Leal J, Delmestri A, Prieto-Alhambra D, Arden NK, Cooper C, Javaid MK, Judge A, REFReSH Study Group (2016) Anti-osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: an interrupted time-series analysis. J Bone Miner Res 31:2008–2015

    Article  CAS  Google Scholar 

  19. Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E (2016) Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int 27:387–396

    Article  CAS  Google Scholar 

  20. Bondo L, Eiken P, Abrahamsen B (2013) Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study. Osteoporos Int 24:245–252

    Article  CAS  Google Scholar 

  21. Lawrence TM, Wenn R, Boulton CT, Moran CG (2010) Age-specific incidence of first and second fractures of the hip. J Bone Joint Surg Br 92:258–261

    Article  CAS  Google Scholar 

  22. Lin TC, Yang CY, Yang YH, Lin SJ (2011) Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther 90:109–116

    Article  CAS  Google Scholar 

  23. Osaki M, Tatsuki K, Hashikawa T, Norimatsu T, Chiba K, Motokawa S, Furuichi I, Doiguchi Y, Aoyagi K, Shindo H (2012) Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int 23:695–703

    Article  CAS  Google Scholar 

  24. Shen SH, Huang KC, Tsai YH, Yang TY, Lee MS, Ueng SW, Hsu RW (2014) Risk analysis for second hip fracture in patients after hip fracture surgery: a nationwide population-based study. J Am Med Dir Assoc 15:725–731

    Article  Google Scholar 

  25. Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PC, Huang KE (2013) Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int 24:511–521

    Article  CAS  Google Scholar 

Download references

Funding

This study is based on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health, Taiwan. This work was supported by China Medical University (grant numbers: CMU107-S-02).

Author information

Authors and Affiliations

  1. Department of Health Services Administration, China Medical University, Taiwan, No.91, Hsueh-Shih Road, Taichung, Taiwan, 40402, Republic of China

    Y.J. Chen, W.Y. Chou & W.C. Tsai

  2. Department of Orthopedic Surgery, China Medical University Hospital, Taiwan, No. 2, Yuh-Der Road, Taichung, Taiwan, 40402, Republic of China

    Y.J. Chen

  3. School of Medicine, China Medical University, No.91, Hsueh-Shih Road, Taichung, Taiwan, 40402, Republic of China

    Y.J. Chen

  4. Department of Health Administration, Asia University, Taiwan, No. 500, Liufeng Road., Wufeng, Taichung, Taiwan, 41354, Republic of China

    P.T. Kung

  5. Department of Medical Research, China Medical University Hospital, China Medical University, No.91, Hsueh-Shih Road, Taichung, Taiwan, Republic of China

    P.T. Kung

Authors
  1. Y.J. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P.T. Kung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W.Y. Chou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W.C. Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W.C. Tsai.

Ethics declarations

Conflicts of interest

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, Y., Kung, P., Chou, W. et al. Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan. Osteoporos Int 31, 1555–1563 (2020). https://doi.org/10.1007/s00198-020-05399-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-020-05399-9

Keywords

Search

Navigation